Flucytosine NDC 60687-599

NDC codes

FDA NDC Directory

Product NDC (as listed)60687-599Labeler and product segments. Claims need a package NDC.

Product NDC at billing width60687-0599Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
60687-599-21	60687059921	30 BLISTER PACK in 1 BOX, UNIT-DOSE (60687-599-21) / 1 CAPSULE in 1 BLISTER PACK (60687-599-11)Marketed from Dec 17, 2021

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Flucytosine
Generic name (nonproprietary): flucytosine
Active ingredients: Flucytosine — 250 mg/1
Dosage form: Capsule
Route: Oral
Labeler: American Health Packaging
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 213665
Marketing start: Dec 17, 2021
Listing expires: Dec 31, 2026
Other FDA classes: Nucleoside Analog (EXT)
Identifiers: Product ID 60687-599_284ff75e-657f-cfe0-e063-6394a90a8cabSPL ID 284ff75e-657f-cfe0-e063-6394a90a8cabSPL set ID 4b1c40b2-e0fb-47d5-b821-889b3090cebeRxCUI 197702, 197703UNII D83282DT06
Pharmacologic class: Nucleoside Analog Antifungal

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N460687059921 followed by a unit qualifier and the quantity

Package 60687-0599-21. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 2, 2024. This label includes a boxed warning.

Indications (excerpt from the label)

INDICATIONS AND USAGE Flucytosine capsules are indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus . Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. Flucytosine capsules should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistan…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 213665

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 213665
Product	Strength	Form · route	Labeler	Product NDC
Flucytosine	Flucytosine 250 mg/1	CapsuleOral	Aurobindo Pharma Limited	59651-331
Flucytosine	Flucytosine 500 mg/1	CapsuleOral	Aurobindo Pharma Limited	59651-332
Flucytosine	Flucytosine 500 mg/1	CapsuleOral	American Health Packaging	60687-610